# EDGAR Filing Document

**Accession Number:** 0001140215
**File Stem:** 0001641172-25-014728
**Filing Date:** 2025-6
**Character Count:** 10726
**Document Hash:** 1f7a739e2366efc7c6f8b68ad620c40d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-014728.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001641172-25-014728

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REED'S, INC.
- **CENTRAL INDEX KEY:** 0001140215
- **STANDARD INDUSTRIAL CLASSIFICATION:** BOTTLED & CANNED SOFT DRINKS CARBONATED WATERS [2086]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 352177773
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-84925
- **FILM NUMBER:** 251040618

**BUSINESS ADDRESS:**
- **STREET 1:** 501 MERRITT 7
- **CITY:** NORWALK
- **STATE:** CT
- **ZIP:** 06851
- **BUSINESS PHONE:** 800 997 3337

**MAIL ADDRESS:**
- **STREET 1:** 501 MERRITT 7
- **CITY:** NORWALK
- **STATE:** CT
- **ZIP:** 06851

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REED'S INC
- **DATE OF NAME CHANGE:** 20140512

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REEDS INC
- **DATE OF NAME CHANGE:** 20020122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ORIGINAL BEVERAGE CORP /
- **DATE OF NAME CHANGE:** 20010508
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Era Regenerative Medicine Ltd
- **CENTRAL INDEX KEY:** 0002053961

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** UNIT 8,3/F., QWOMAR TRADING COMPLEX,
- **STREET 2:** BLACKBURNE ROAD, PORT PURCELL, ROAD TOWN
- **CITY:** TORTOLA
- **STATE:** D8
- **ZIP:** VG1110
- **BUSINESS PHONE:** 646-656-8327

**MAIL ADDRESS:**
- **STREET 1:** UNIT 8,3/F., QWOMAR TRADING COMPLEX,
- **STREET 2:** BLACKBURNE ROAD, PORT PURCELL, ROAD TOWN
- **CITY:** TORTOLA
- **STATE:** D8
- **ZIP:** VG1110

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Reed's, Inc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**758338305**

*(CUSIP Number)*

**Ruba Qashu**<br>Procopio, Cory, Hargreaves & Savitch LLP<br>12544 High Bluff Drive, Suite 400<br>San Diego CA 92130<br>9493555405

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/04/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **758338305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Era Regenerative Medicine Ltd** | Name of reporting person<br>**Era Regenerative Medicine Ltd** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**28214789.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**28214789.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**28214789.00** | Aggregate amount beneficially owned by each reporting person<br>**28214789.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**57.8%** | Percent of class represented by amount in Row (11)<br>**57.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

**Comment for Reporting Person:** Company formed under laws of British Virgin Islands

| **CUSIP No.** | **758338305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**D&D Source of Life Holding Ltd.** | Name of reporting person<br>**D&D Source of Life Holding Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**28214789.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**28214789.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**28214789.00** | Aggregate amount beneficially owned by each reporting person<br>**28214789.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**57.8%** | Percent of class represented by amount in Row (11)<br>**57.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** A company formed under the laws of the Cayman Islands

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Reed's, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
501 Merritt 7, NORWALK, CT, 06851

**Item 4. Purpose of Transaction**

On December 31, 2024, all outstanding shares of D&D were assigned to ERM as a holding company for restructuring purposes without requirement of payment of consideration. Dai Siqi, currently the sole director of ERM, has voting and dispositive power over the securities of the Issuer held directly by D&D. D&D acquired the Issuer's shares, and may acquire the shares issuable upon exercise of the Issuer's warrants for investment purposes, and such purchases have been, and will be, made in D&D's ordinary course of business as an investment and for expansion of business. D&D worked with the Issuer to amend the Issuer's bylaws to give a majority stockholder the ability to call a stockholders meeting and other rights reasonable and customary for operation of a controlled company. All changes to the Issuer's bylaws were approved by the Issuer's board of directors. D&D has in the past, and the Reporting Persons may in the future, engage in discussions with the Issuer's management, board of directors, and/or other stockholders or third parties covering a broad range of subjects, including relative to performance, strategic direction, capital allocation, strategic financing opportunities or other transactions involving the Issuer, stockholder value, composition of the board of directors, and governance and/or ownership of the Issuer. Except as set forth in this Item, the Reporting Persons have no present plans or proposals which relate to or would result in any of the matters set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Persons share voting and dispositive control of 28,214,789 shares of common stock of the Issuer; 57.8%. The calculation is based on a denominator of 48,829,161 which includes (i) 45,371,247 shares of common stock outstanding as of May 9, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed on May 14, 2025, (2) 3,225,806 shares of common stock issued and sold by the Issuer on June 4, 2025, as disclosed in the Issuer's Form 8-K filed on June 4, 2025, and (2) 232,108 shares of common stock issuable upon exercise of currently exercisable warrants.

**(b)**
The Reporting Persons share voting and dispositive control of 28,214,789 shares of common stock of the Issuer; 57.8%.

**(c)**
On December 31, 2024, all outstanding shares of D&D were assigned to ERM as a holding company for restructuring purposes without requirement of payment of consideration. Dai Siqi is currently the sole director of ERM and has voting and dispositive power over the securities of the Issuer held directly by D&D. On June 4, 2025, D&D purchased 1,075,269 shares of common stock of the Issuer in the Issuer's PIPE transaction at a purchase price of $0.93 per share for an aggregate purchase price of $1,000,000. Except as set forth above no transactions in the Issuer's common stock were effected by the Reporting Persons during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

None.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Era Regenerative Medicine Ltd

**Signature:** /s/ Dai Siqi

**Name/Title:** Dai Siqi, Director

**Date:** 06/10/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** D&D Source of Life Holding Ltd.

**Signature:** /s/ Dai Siqi

**Name/Title:** Dai Siqi, on behalf of Era Regenerative Medicine Ltd as its Director

**Date:** 06/10/2025